• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Guided Therapeutics Inc (OP:GTHP)

    0.2351 -0.0149 (-5.96%)
    Streaming Delayed Price Updated: 1:52 PM EDT, May 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Guided Therapeutics Inc

    News headline image
    Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Makes Initial Shipment to New Chinese Distribution Partner Hangzhou Dongye Medical Technology, Ltd.
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Receives $100,000 from SMI’s Investment Partners to Continue Commercialization Process of LuViva in China
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Announces New Agreement and Purchase Orders from Shandong Yaohua Medical Instrument Corporation
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Closes $3.3 Million Bridge Financing
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 Payment
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical Requirements
    From Guided Therapeutics, Inc.
    Via Business Wire
    News headline image
    Guided Therapeutics Replaces Convertible Note Facility and Significantly Reduces Dilution
    From Guided Therapeutics, Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.